Intelligent Bio Solutions Inc (INBS) FinancialsINBSIntelligent Bio Solutions Inc

Intelligent Bio Solutions Inc (INBS) generates its revenue primarily from Commercially available Intelligent Fingerprinting Products , which accounts for 93.6% of total sales, equivalent to $789.64K. Understanding this concentration is critical for investors evaluating how INBS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Intelligent Bio Solutions Inc maintains a gross margin of 21.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -345.99%, while the net margin is -341.89%. These profitability ratios, combined with a Return on Equity (ROE) of -292.25%, provide a clear picture of how effectively INBS converts its operational activities into shareholder value.

In the context of the broader market, INBS competes directly with industry leaders such as TNON and OGCP. With a market capitalization of $6.61M, it holds a significant position in the sector. When comparing efficiency, INBS's gross margin of 21.68% stands against TNON's 63.64% and OGCP's N/A. Such benchmarking helps identify whether Intelligent Bio Solutions Inc is trading at a premium or discount relative to its financial performance.

The company has shown increasing total revenue, with Q4 2026 revenue at 1,145,802 USD, up from 607,494 USD in Q2 2025. Gross margin has improved significantly, reaching 21.68% in Q4 2026, up from -13.51% in Q2 2025, indicating better operational efficiency.